BidaskClub upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a sell rating to a hold rating in a research report released on Tuesday.

ACRS has been the subject of several other research reports. Zacks Investment Research raised shares of Aclaris Therapeutics from a hold rating to a buy rating and set a $31.00 target price for the company in a research note on Tuesday, October 10th. Cantor Fitzgerald set a $50.00 target price on shares of Aclaris Therapeutics and gave the stock a buy rating in a research note on Wednesday, October 4th. ValuEngine lowered shares of Aclaris Therapeutics from a hold rating to a sell rating in a research note on Tuesday, September 12th. Finally, JMP Securities reissued an outperform rating and issued a $39.00 price objective on shares of Aclaris Therapeutics in a research note on Friday, September 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $39.20.

Aclaris Therapeutics (NASDAQ ACRS) traded down $1.42 during trading on Tuesday, reaching $23.30. 1,073,776 shares of the company traded hands, compared to its average volume of 282,596. Aclaris Therapeutics has a 52-week low of $21.32 and a 52-week high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.23. The company had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $2.00 million. analysts predict that Aclaris Therapeutics will post -2.59 EPS for the current year.

Institutional investors have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. lifted its stake in Aclaris Therapeutics by 40.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 61,765 shares of the biotechnology company’s stock worth $1,676,000 after acquiring an additional 17,804 shares during the last quarter. Franklin Resources Inc. lifted its stake in Aclaris Therapeutics by 55.4% in the second quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock worth $53,030,000 after acquiring an additional 697,104 shares during the last quarter. Cadence Capital Management LLC purchased a new position in Aclaris Therapeutics in the third quarter worth approximately $689,000. Rosenblum Silverman Sutton S F Inc. CA lifted its stake in Aclaris Therapeutics by 17.3% in the second quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 38,400 shares of the biotechnology company’s stock worth $1,041,000 after acquiring an additional 5,650 shares during the last quarter. Finally, Citadel Advisors LLC lifted its stake in Aclaris Therapeutics by 620.6% in the third quarter. Citadel Advisors LLC now owns 242,016 shares of the biotechnology company’s stock worth $6,247,000 after acquiring an additional 208,429 shares during the last quarter. Institutional investors own 92.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Aclaris Therapeutics (ACRS) Raised to “Hold” at BidaskClub” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/aclaris-therapeutics-acrs-raised-to-hold-at-bidaskclub/1765927.html.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.